Biomarin Pharmaceutical Inc. - Registered Shares

NASDAQ:BMRN  
90.74
+0.63 (+0.70%)
6:36:43 PM EDT: $93.32 +2.58 (+2.84%)
Products

FDA Approves First Drug To Improve Growth In Children With Most Common Form Of Dwarfism

Published: 11/19/2021 19:11 GMT
Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) - FDA Approves First Drug to Improve Growth in Children With Most Common Form of Dwarfism.
FDA - Granted Approval of Voxzogo (vosoritide) Injection to Biomarin.